MOTS-c vs SS-31 (Elamipretide): What Is the Difference?

Both are mitochondrial, but one signals and one binds a lipid. MOTS-c is a short peptide encoded within mitochondrial DNA itself, described in 2015 and proposed to act as a signalling molecule that reaches out to influence metabolism elsewhere in the cell 1. SS-31, developed under the name elamipretide, is a designed synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid specific to that membrane 23. One is a message; the other is a structural intervention. Grouping them as mitochondrial peptides describes where they end up, not what they do, and the two have almost nothing else in common — including their evidence, which is the part most comparisons leave out.

What is MOTS-c?

A 16-amino-acid peptide encoded inside the mitochondrial genome, which is the genuinely unusual thing about it. Mitochondria carry their own small circle of DNA, and for a long time the short list of genes on it was assumed to be complete. MOTS-c was identified within a region coding for one of the mitochondrial ribosomal RNAs, in a reading frame that had not previously been recognised as productive 1.

That is an important structural point rather than a piece of trivia. If the peptide is a real gene product, it is a molecule the cell already makes, and the concept it belongs to is that mitochondria send messages outward rather than only receiving instructions. The original report proposed exactly that: the peptide was described as affecting folate and purine metabolism, with a downstream consequence for a central cellular energy sensor, and mice given it were reported to resist diet-induced obesity and insulin resistance 1.

The limits of that evidence should be stated as plainly as the finding. The 2015 report is a substantial piece of molecular biology, and it is mouse and cell work. Human research since has largely consisted of observational and association studies — measuring circulating concentrations of the peptide in people and relating them to metabolic status, ageing or exercise. Those studies establish that the peptide exists in humans and that its concentration varies. They do not establish what happens when it is administered, because that trial has not been run at any comparable scale.

What is SS-31?

A designed synthetic tetrapeptide, one of a numbered series, built to accumulate in the inner mitochondrial membrane. It has no natural counterpart; the sequence exists because chemists constructed it. The series that produced it was reported in 2004, characterised by alternating aromatic and positively charged residues, a combination that lets the peptides cross cell membranes without a transporter and then concentrate in mitochondria 2.

The original description framed these compounds as targeted antioxidants, and that framing has since been substantially revised — which is a mark in the programme's favour rather than against it. Later work identified the binding partner: cardiolipin, a distinctive four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane, where it organises the protein complexes of the electron transport chain 3. SS-31 associates with cardiolipin, and the proposed consequence is a change in how cardiolipin interacts with those complexes, improving the efficiency of electron transport in tissue that has been starved of oxygen 3.

Note how different that is from a signal. MOTS-c is proposed to work by carrying information to machinery elsewhere. SS-31 is proposed to work by physically sitting in a membrane and changing the local environment of proteins already there. Those are not two flavours of one mechanism, and no result about either transfers to the other.

Which one has human clinical trial data?

Elamipretide, decisively. It has been through a registered clinical development programme spanning several conditions, with randomised placebo-controlled trials, pre-specified endpoints and published results. MOTS-c has nothing of that kind.

That asymmetry deserves emphasis because it inverts the usual pattern on this subject. Most compounds discussed in this space have no human trials at all, and articles about them end up comparing two piles of rodent data. Here, one side of the comparison has been tested properly in patients, which means there is something real to report — and what there is to report is largely negative.

Before that, the honest version of the MOTS-c position. The absence of trials is not a verdict. It reflects where the compound sits in its development arc: a molecule described in 2015, still mostly the subject of mechanistic and observational research, with no completed programme to report on. An untested compound and a tested-and-failed compound occupy different categories, and conflating them is unfair in both directions.

What did the elamipretide trials actually find?

The two largest published trials did not meet their primary endpoints. This is the part vendor comparisons omit, and it is the single most informative fact available about either compound on this page.

In primary mitochondrial myopathy — an inherited disorder of mitochondrial function, and about as direct a test of a mitochondrial mechanism as clinical medicine offers — a randomised placebo-controlled phase 3 trial assessed elamipretide over 24 weeks. It did not show a significant benefit on its primary endpoints, which paired a measure of walking distance with a patient-reported fatigue score 4. The trial had been designed on the strength of an earlier crossover study in the same programme that had produced an encouraging signal at the highest quantity tested. That earlier signal did not survive the larger, longer trial, which is one of the most familiar and instructive trajectories in drug development.

In heart failure with reduced ejection fraction, a phase 2 trial examined left ventricular function and likewise did not demonstrate a significant improvement in its primary imaging endpoint against placebo 5. That study was short, which limits what can be concluded from it in isolation, and the limitation cuts both ways: it is not strong evidence of no effect, but it is certainly not evidence of one.

A fair account should also say what these results do not establish. Missing a primary endpoint in a specific population, at a specific quantity, over a specific duration, on a specific measure is a defeat for that hypothesis rather than a refutation of the underlying biology. Cardiolipin binding is a real molecular interaction whether or not a walking test moves 3. Development in other conditions has continued after these results. The correct reading is neither that the mechanism is disproven nor that the failures can be waved away, but that a plausible mechanism was tested where it should work best and did not produce the expected clinical benefit — which is exactly the kind of outcome mechanism-first reasoning is bad at predicting.

Is mitochondrial peptide a real category?

No, not in any useful sense. It is a description of destination, not of mechanism, origin or evidence, and treating it as a class is how two entirely unrelated compounds end up on the same product page being discussed as alternatives.

Consider what the label conceals here. One compound is a natural gene product read out of the mitochondrial genome; the other is a synthetic construct with no counterpart in biology. One is proposed to act by carrying a signal away from the mitochondrion; the other by lodging in its membrane. One has mouse metabolic data and human association studies; the other has failed phase 3 data. There is no proposition true of both that is not also true of a very long list of other molecules.

The category also carries a rhetorical payload worth naming. Mitochondria are genuinely central to energy metabolism and genuinely implicated in ageing, so anything labelled mitochondrial inherits an aura of fundamental importance. That is a category effect, not evidence. The useful questions run the other way and are the same ones asked anywhere else: what is the molecule, what does it bind, what has been measured, in what species, against what control, and did the result hold when the study got bigger 45.

So the short answer. MOTS-c is a signal your own mitochondria encode, interesting mainly for what it implies about how mitochondria communicate, and supported by mouse and observational human work. SS-31 is a designed peptide that binds a membrane lipid, supported by clear molecular evidence and by clinical trials that came back negative on their main questions. They are not competitors, they are not alternatives, and the only thing they share is a compartment.